Digital Ischemia and Abdominal Pain: Which Second Agent for Lupus Vasculitis, and How Fast
Her fingertips are turning black and her abdomen hurts in a way she's never described before. The disagreement over which drug to add can't actually be settled until a scan the group hasn't seen yet comes back — which is itself the point.
M.R., a 33-year-old woman who coaches high school volleyball, presented to the emergency department with three days of worsening periumbilical abdominal pain, now with new nailfold infarcts and a cold, dusky fourth fingertip on her left hand. She has SLE diagnosed six years ago with a history of cutaneous involvement only, currently on hydroxychloroquine and low-dose prednisone, and had been stable until this week. Her exam shows diffuse abdominal tenderness without peritoneal signs yet, a livedoid pattern on both forearms, and the affected fingertip is cool to the touch with a capillary refill delayed beyond three seconds — a real, evolving ischemic process, not a chronic finding being newly noticed. She coached a tournament over the weekend and put the fingertip down to cold gym air conditioning, which held as an explanation until the abdominal pain arrived and stopped fitting it.
Lupus-associated vasculitis can range from isolated cutaneous small-vessel disease, generally not organ- or life-threatening, to mesenteric vasculitis, which carries a real risk of bowel ischemia and perforation if missed or treated too slowly. Her digital finding argues for at least small-vessel vasculitis somewhere; her abdominal pain, new and severe enough to bring her to the emergency department rather than call the clinic, is the finding that actually determines how urgently she needs to be treated — and that determination depends on a CT angiogram the group does not have back yet. The 2025 ACR guideline is unambiguous that systemic vasculitis from active lupus is treated with pulse or high-dose glucocorticoids plus an immunosuppressant or biologic rather than glucocorticoids alone, and conditionally prefers IV cyclophosphamide or anti-CD20 therapy in the more severe presentations — so the steroid is not in dispute and the guideline itself makes severity the variable that picks the second agent. Severity is precisely what nobody in the room can yet state, which leaves the answer to ‘how sick is she’ sitting in radiology.
Emergency consult, before the scan is back
A cold, ischemic fingertip plus new severe abdominal pain in someone with known lupus vasculitis risk — that combination is exactly the picture that precedes bowel infarction if we wait too long. The 2025 ACR guideline conditionally prefers IV cyclophosphamide or anti-CD20 for the severe end of lupus vasculitis, and I think that's where she is. I'd start cyclophosphamide now, on top of pulse steroids, rather than lose time to imaging that could take another hour to come back.
I hear the urgency, but cyclophosphamide is a real toxicity burden — gonadotoxic, myelosuppressive, hemorrhagic cystitis risk — and we don't yet know if her disease is mesenteric-severe or a milder process limited mostly to skin and digits. Mycophenolate has a faster, better-tolerated onset and would be a reasonable first step if the scan comes back reassuring.
I'm not arguing against escalation if the imaging confirms real mesenteric involvement — I'm arguing against committing to the most toxic option before we know that's what we're actually treating.
Both of you are arguing about which immunosuppressive to start, and neither drug touches the actual emergency in the room right now, which is whether she has bowel ischemia needing a surgeon before either of you gets to prescribe anything.
The CT angiogram has to come back before the drug decision is finalized — that's not delaying her care, that's making sure we're treating the right problem. I'd start pulse steroids now, which nobody disputes, and hold the specific second agent for imaging. One caveat I want on the record, since we'll be relying on her exam while we wait: high-dose steroids blunt peritoneal signs. Once they're running, a soft abdomen means less than it did an hour ago, and that shifts the weight onto the scan and onto serial lactate rather than onto my hands.
Agreed: start pulse IV methylprednisolone immediately — the one point no voice contested — and hold both cyclophosphamide and mycophenolate ready, pending the CT angiogram result, rather than choosing between them blind.
cyclophosphamide starts immediately, and the toxicity-avoidance argument is set aside in favor of treating a confirmed, organ-threatening process.
mycophenolate starts instead, and her presentation is treated as severe cutaneous/digital vasculitis without the added toxicity cyclophosphamide would have meant.
Not fully settled even once the scan returns: whether the group should have started cyclophosphamide empirically the moment digital ischemia appeared, rather than waiting on imaging at all — the rheumatologist's original urgency wasn't overruled, only sequenced behind a diagnostic step the emergency physician insisted had to come first.